Imricor Research Development vs Net Income From Continuing Ops Analysis

IMR Stock

1.14 0.02 1.72%

Imricor Medical financial indicator trend analysis is infinitely more than just investigating Imricor Medical Systems recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Imricor Medical Systems is a good investment. Please check the relationship between Imricor Medical Research Development and its Net Income From Continuing Ops accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imricor Medical Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Research Development vs Net Income From Continuing Ops

Research Development vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Imricor Medical Systems Research Development account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.

The correlation between Imricor Medical's Research Development and Net Income From Continuing Ops is -0.76. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Imricor Medical Systems, assuming nothing else is changed. The correlation between historical values of Imricor Medical's Research Development and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Imricor Medical Systems are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Research Development i.e., Imricor Medical's Research Development and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.76

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Research Development

Net Income From Continuing Ops

Most indicators from Imricor Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Imricor Medical Systems current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imricor Medical Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Issuance Of Capital Stock is likely to gain to about 10.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 3.9 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	918.1K	1.0M	707.5K	525.5K
Interest Income	16.7K	108.0K	63.0K	59.9K

Depreciation And Amortization Interest Income

Imricor Medical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets
Total Assets		0.11	0.11	0.33	0.83	-0.77	0.89	0.76	0.78	-0.72	-0.33	0.26	0.89	0.71	0.44	0.1	0.19	0.89	0.45	0.0	-0.24	0.67	0.32	0.29	-0.2	0.96
Short Long Term Debt Total	0.11		0.77	0.71	-0.3	-0.48	-0.04	0.45	0.13	0.44	-0.74	0.71	-0.19	0.51	0.77	-0.71	0.88	-0.19	0.47	0.58	0.66	0.33	0.56	0.57	0.62	-0.06
Other Current Liab	0.11	0.77		0.95	-0.44	-0.47	0.23	0.5	0.31	0.55	-0.9	0.98	-0.27	0.55	0.8	-0.95	0.53	-0.27	0.58	-0.04	0.91	0.47	0.64	0.69	0.91	-0.08
Total Current Liabilities	0.33	0.71	0.95		-0.23	-0.64	0.46	0.69	0.57	0.39	-0.98	0.99	-0.08	0.71	0.79	-0.89	0.47	-0.08	0.77	-0.14	0.8	0.69	0.79	0.83	0.82	0.14
Total Stockholder Equity	0.83	-0.3	-0.44	-0.23		-0.48	0.67	0.45	0.49	-0.96	0.2	-0.29	0.96	0.4	0.01	0.63	-0.06	0.96	0.08	0.07	-0.74	0.36	-0.09	-0.15	-0.7	0.91
Other Liab	-0.77	-0.48	-0.47	-0.64	-0.48		-0.74	-0.96	-0.67	0.25	0.7	-0.6	-0.48	-0.96	-0.77	0.27	-0.42	-0.48	-0.72	-0.1	-0.09	-0.85	-0.67	-0.6	-0.12	-0.64
Net Tangible Assets	0.89	-0.04	0.23	0.46	0.67	-0.74		0.8	0.87	-0.57	-0.45	0.4	0.75	0.74	0.39	-0.07	-0.02	0.75	0.59	-0.41	-0.08	0.8	0.43	0.41	-0.01	0.86
Property Plant And Equipment Net	0.76	0.45	0.5	0.69	0.45	-0.96	0.8		0.75	-0.24	-0.75	0.63	0.49	0.99	0.72	-0.34	0.44	0.49	0.82	-0.01	0.15	0.95	0.71	0.64	0.19	0.66
Current Deferred Revenue	0.78	0.13	0.31	0.57	0.49	-0.67	0.87	0.75		-0.35	-0.6	0.47	0.58	0.68	0.29	-0.25	0.11	0.58	0.78	-0.34	0.09	0.85	0.66	0.7	0.18	0.73
Net Debt	-0.72	0.44	0.55	0.39	-0.96	0.25	-0.57	-0.24	-0.35		-0.39	0.43	-0.94	-0.19	0.13	-0.72	0.14	-0.94	0.13	-0.03	0.79	-0.16	0.33	0.35	0.76	-0.85
Retained Earnings	-0.33	-0.74	-0.9	-0.98	0.2	0.7	-0.45	-0.75	-0.6	-0.39		-0.94	0.08	-0.76	-0.76	0.86	-0.52	0.08	-0.86	0.07	-0.74	-0.77	-0.89	-0.9	-0.77	-0.14
Accounts Payable	0.26	0.71	0.98	0.99	-0.29	-0.6	0.4	0.63	0.47	0.43	-0.94		-0.13	0.67	0.83	-0.9	0.48	-0.13	0.67	-0.12	0.82	0.61	0.7	0.76	0.84	0.07
Cash	0.89	-0.19	-0.27	-0.08	0.96	-0.48	0.75	0.49	0.58	-0.94	0.08	-0.13		0.44	0.12	0.46	0.06	1.0	0.13	0.04	-0.57	0.41	-0.07	-0.09	-0.53	0.97
Non Current Assets Total	0.71	0.51	0.55	0.71	0.4	-0.96	0.74	0.99	0.68	-0.19	-0.76	0.67	0.44		0.78	-0.37	0.51	0.44	0.8	0.06	0.2	0.91	0.68	0.62	0.22	0.61
Non Currrent Assets Other	0.44	0.77	0.8	0.79	0.01	-0.77	0.39	0.72	0.29	0.13	-0.76	0.83	0.12	0.78		-0.6	0.65	0.12	0.47	0.27	0.51	0.53	0.48	0.46	0.49	0.27
Other Assets	0.1	-0.71	-0.95	-0.89	0.63	0.27	-0.07	-0.34	-0.25	-0.72	0.86	-0.9	0.46	-0.37	-0.6		-0.45	0.46	-0.58	0.12	-0.98	-0.39	-0.66	-0.72	-0.98	0.28
Long Term Debt	0.19	0.88	0.53	0.47	-0.06	-0.42	-0.02	0.44	0.11	0.14	-0.52	0.48	0.06	0.51	0.65	-0.45		0.06	0.36	0.73	0.39	0.3	0.32	0.34	0.34	0.13
Cash And Short Term Investments	0.89	-0.19	-0.27	-0.08	0.96	-0.48	0.75	0.49	0.58	-0.94	0.08	-0.13	1.0	0.44	0.12	0.46	0.06		0.13	0.04	-0.57	0.41	-0.07	-0.09	-0.53	0.97
Common Stock Shares Outstanding	0.45	0.47	0.58	0.77	0.08	-0.72	0.59	0.82	0.78	0.13	-0.86	0.67	0.13	0.8	0.47	-0.58	0.36	0.13		-0.19	0.42	0.93	0.94	0.91	0.48	0.34
Long Term Debt Total	0.0	0.58	-0.04	-0.14	0.07	-0.1	-0.41	-0.01	-0.34	-0.03	0.07	-0.12	0.04	0.06	0.27	0.12	0.73	0.04	-0.19		-0.11	-0.22	-0.13	-0.17	-0.19	-0.02
Non Current Liabilities Total	-0.24	0.66	0.91	0.8	-0.74	-0.09	-0.08	0.15	0.09	0.79	-0.74	0.82	-0.57	0.2	0.51	-0.98	0.39	-0.57	0.42	-0.11		0.2	0.52	0.59	0.99	-0.41
Capital Surpluse	0.67	0.33	0.47	0.69	0.36	-0.85	0.8	0.95	0.85	-0.16	-0.77	0.61	0.41	0.91	0.53	-0.39	0.3	0.41	0.93	-0.22	0.2		0.81	0.76	0.26	0.59
Other Current Assets	0.32	0.56	0.64	0.79	-0.09	-0.67	0.43	0.71	0.66	0.33	-0.89	0.7	-0.07	0.68	0.48	-0.66	0.32	-0.07	0.94	-0.13	0.52	0.81		0.94	0.57	0.15
Other Stockholder Equity	0.29	0.57	0.69	0.83	-0.15	-0.6	0.41	0.64	0.7	0.35	-0.9	0.76	-0.09	0.62	0.46	-0.72	0.34	-0.09	0.91	-0.17	0.59	0.76	0.94		0.64	0.12
Total Liab	-0.2	0.62	0.91	0.82	-0.7	-0.12	-0.01	0.19	0.18	0.76	-0.77	0.84	-0.53	0.22	0.49	-0.98	0.34	-0.53	0.48	-0.19	0.99	0.26	0.57	0.64		-0.36
Total Current Assets	0.96	-0.06	-0.08	0.14	0.91	-0.64	0.86	0.66	0.73	-0.85	-0.14	0.07	0.97	0.61	0.27	0.28	0.13	0.97	0.34	-0.02	-0.41	0.59	0.15	0.12	-0.36

Click cells to compare fundamentals

Imricor Medical Account Relationship Matchups

Imricor Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.5M	33.6M	26.9M	13.7M	8.3M	15.9M
Short Long Term Debt Total	1.3M	1.4M	1.7M	4.5M	10.4M	10.9M
Other Current Liab	388.6K	503.2K	175.3K	23.4K	3.9M	4.1M
Total Current Liabilities	1.4M	2.3M	2.7M	2.1M	6.7M	7.0M
Total Stockholder Equity	7.0M	28.8M	22.4M	7.5M	(12.8M)	(12.2M)
Other Liab	592.9K	617.2K	509.6K	536.9K	483.2K	459.0K
Net Tangible Assets	7.0M	28.8M	22.4M	7.5M	8.6M	8.3M
Property Plant And Equipment Net	2.7M	3.9M	3.6M	3.6M	4.6M	2.9M
Net Debt	(4.9M)	(23.8M)	(16.8M)	(1.2M)	9.6M	10.1M
Retained Earnings	(40.4M)	(52.9M)	(72.6M)	(90.0M)	(165.0M)	(156.7M)
Accounts Payable	541.0K	529.1K	686.7K	259.3K	2.1M	2.2M
Cash	5.0M	25.1M	18.5M	5.7M	831.5K	789.9K
Non Current Assets Total	3.7M	4.6M	4.2M	4.0M	6.4M	3.7M
Non Currrent Assets Other	969.2K	754.7K	288.0K	119.1K	1.5M	1.6M
Other Assets	1.0M	969.2K	754.7K	565.2K	(3.9M)	(3.7M)
Long Term Debt	2.3M	9.6M	0.0	2.2M	8.6M	4.5M
Cash And Short Term Investments	5.0M	25.1M	18.5M	5.7M	831.5K	789.9K
Long Term Debt Total	1.1M	668.3K	226.7K	2.2M	2.0M	2.0M
Liabilities And Stockholders Equity	10.5M	33.6M	26.9M	13.7M	8.3M	15.9M
Non Current Liabilities Total	2.1M	2.5M	1.7M	4.1M	18.3M	19.2M
Capital Surpluse	47.4M	81.7M	95.0M	97.5M	112.1M	59.6M
Inventory	1.2M	3.1M	2.6M	2.3M	1.7M	1.6M
Other Current Assets	287.8K	491.6K	1.5M	3.2M	2.6M	2.7M
Total Liab	3.5M	4.8M	4.5M	6.2M	17.1M	17.9M
Total Current Assets	6.8M	28.9M	22.7M	9.7M	5.8M	5.5M
Short Term Debt	127.3K	198.0K	518.7K	867.2K	667.9K	376.4K
Common Stock	47.5M	81.7M	95.0M	97.5M	24.8K	23.5K
Property Plant Equipment	2.7M	3.9M	3.6M	3.6M	4.1M	2.6M
Net Receivables	256.3K	223.2K	94.7K	125.5K	392.6K	412.2K
Capital Lease Obligations	694.0K	1.8M	1.7M	2.3M	1.4M	1.4M
Net Invested Capital	10.0M	37.4M	22.4M	9.7M	227.9K	216.5K
Property Plant And Equipment Gross	3.9M	5.3M	5.5M	6.1M	6.4M	5.5M
Capital Stock	47.5M	81.7M	95.0M	97.5M	103.8M	86.7M
Net Working Capital	7.7M	34.6M	20.0M	7.6M	(628.2K)	(596.8K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Imricor Stock Analysis

When running Imricor Medical's price analysis, check to measure Imricor Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imricor Medical is operating at the current time. Most of Imricor Medical's value examination focuses on studying past and present price action to predict the probability of Imricor Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imricor Medical's price. Additionally, you may evaluate how the addition of Imricor Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC